MannKind Overview

  • Year Founded
  • 1991

Year Founded

  • Status
  • Public

  • Employees
  • 592

Employees

  • Stock Symbol
  • MNKD

Stock Symbol

  • Investments
  • 5

  • Share Price
  • $4.07
  • (As of Wednesday Closing)

MannKind General Information

Description

MannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

Contact Information

Formerly Known As
Pharmaceutical Discovery
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1 Casper Street
  • Danbury, CT 06810
  • United States
+1 (818)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 1 Casper Street
  • Danbury, CT 06810
  • United States
+1 (818)

MannKind Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MannKind Stock Performance

As of 18-Nov-2026, MannKind’s stock price is $4.07. Its current market cap is $1.31B with 322M shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.07 $4.07 $2.23 - $6.51 $1.31B 322M 3.93M -$0.24

MannKind Financials Summary

As of 30-Sep-2026, MannKind has a trailing 12-month revenue of $413M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,473,741 1,600,963 1,933,941 1,117,762
Revenue 413,371 348,966 285,504 198,962
EBITDA (7,639) 43,460 63,046 12,957
Net Income (74,822) 5,863 27,588 (11,938)
Total Assets 722,616 792,182 393,843 475,198
Total Debt 330,728 367,440 50,119 272,624
Public Fundamental Data provided by Morningstar, Inc. disclaimer

MannKind Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore MannKind‘s full profile, request access.

Request a free trial

MannKind Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
MannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solu
Drug Discovery
Danbury, CT
592 As of 2025

Madison, WI

Cambridge, MA
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

MannKind Competitors (50)

One of MannKind’s 50 competitors is Regenerative Medical Solutions, a Venture Capital-Backed company based in Madison, WI.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Regenerative Medical Solutions Venture Capital-Backed Madison, WI
AnTolRx Formerly VC-backed Cambridge, MA
Apexian Pharmaceuticals Venture Capital-Backed Indianapolis, IN
Altimmune Formerly VC-backed Gaithersburg, MD
uniQure Formerly VC-backed Amsterdam, Netherlands
You’re viewing 5 of 50 competitors. Get the full list »

MannKind Patents

MannKind Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026236643-A1 Methods for treating non-tuberculous mycobacterial infection Pending 08-May-2025
WO-2026164905-A1 Stabilization apparatus for a dry powder vessel Pending 28-Jan-2025
US-20260207630-A1 Furosemide formulations Pending 13-Jan-2025
WO-2026142985-A1 Methods for the manufacture of diketopiperazine derivatives Pending 23-Dec-2024
WO-2026064480-A1 Method and composition for treating lung diseases Pending 18-Sep-2024 A61K9/0075
To view MannKind’s complete patent history, request access »

MannKind Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MannKind Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore MannKind‘s full profile, request access.

Request a free trial

MannKind Investments & Acquisitions (5)

MannKind’s most recent deal was a Merger/Acquisition with ScPharmaceuticals for . The deal was made on 07-Oct-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ScPharmaceuticals 07-Oct-2025 Merger/Acquisition Other Pharmaceuticals and Biotechnology
V-Go Insulin Delivery Device 17-May-2022 Merger/Acquisition Therapeutic Devices
QrumPharma 07-Dec-2020 Merger/Acquisition Drug Discovery
Pfizer (Insulin Assets) 22-Jun-2009 Corporate Asset Purchase Buildings and Property
Allecure 12-Dec-2001 Merger/Acquisition Pharmaceuticals
To view MannKind’s complete investments and acquisitions history, request access »

MannKind ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

29.76 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view MannKind’s complete esg history, request access »

MannKind Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
ScPharmaceuticals Burlington, MA 2013

MannKind FAQs

  • When was MannKind founded?

    MannKind was founded in 1991.

  • Where is MannKind headquartered?

    MannKind is headquartered in Danbury, CT.

  • What is the size of MannKind?

    MannKind has 592 total employees.

  • What industry is MannKind in?

    MannKind’s primary industry is Drug Discovery.

  • Is MannKind a private or public company?

    MannKind is a Public company.

  • What is MannKind’s stock symbol?

    The ticker symbol for MannKind is MNKD.

  • What is the current stock price of MannKind?

    As of 18-Nov-2026 the stock price of MannKind is $4.07.

  • What is the current market cap of MannKind?

    The current market capitalization of MannKind is $1.31B.

  • What is MannKind’s current revenue?

    The trailing twelve month revenue for MannKind is $413M.

  • Who are MannKind’s competitors?

    Regenerative Medical Solutions, AnTolRx, Apexian Pharmaceuticals, Altimmune, and uniQure are some of the 50 competitors of MannKind.

  • What is MannKind’s annual earnings per share (EPS)?

    MannKind’s EPS for 12 months was -$0.24.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process